FAST NEWS: Simcere’s profit plunges on investment losses
The Latest: Simcere Pharmaceutical Group Ltd. (2096.HK) on Tuesday forecast its net profit for the first half of this year will be between 427 million yuan ($48.9 million) and 487 million yuan,…
Profit setback for Simcere Pharma in novel drugs quest
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
FAST NEWS: Simcere’s Covid drug trial shows promising results
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Thursday that newly published results of a Phase 2/3 clinical study for its innovative drug, Xiannuoxin, for the treatment of adult patients…
FAST NEWS: Simcere gets exclusive rights to innovative influenza drug
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Tuesday that it has signed a deal giving it exclusive commercialization rights for treatment of influenza indications using the innovative drug ADC189 from Jiaxing…
FAST NEWS: Simcere’s revenue jumps on rising innovative drug sales
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) said on Thursday it expects to report its revenue grew between 24% and 26.3% to between 3.35 billion yuan ($468 million) and 3.41 billion yuan in…
Drug maker Junshi seeks Swiss cure for cash woes
The biotech aims to raise 3.4 billion yuan through Swiss GDRs in its second major fund-raising push in just over six months Key Takeaways: Junshi Biosciences reported dismal results in…
Missing the Covid boat, Junshi stumbles back to old business
Despite developing an oral drug to treat Covid, the biotech company's revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: Junshi Bioscience's…
Recent Articles
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK
688150.SHG
Missing the Covid boat, Junshi stumbles back to old business
1877.HK
688180.SHG
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Innogen Pharma jostles for a slice of the weight-loss market
